Uncategorized

Beam’s Base Editor Advances to Pivotal Development on Back of ‘Impressive’ AATD Data

Published

2 weeks ago

on

Beam is now in the strongest position of all companies advancing a genetic therapy for alpha-1 antitrypsin deficiency, according to analysts at William Blair.

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version